Overview
Wilms tumour, also known as nephroblastoma, is the most common type of kidney cancer in children. It accounts for approximately 90% of all paediatric renal malignancies and represents 5–6% of all childhood cancers. Thanks to decades of international collaborative clinical trials—primarily led by the Children’s Oncology Group (COG) in North America and the International Society of Paediatric Oncology (SIOP) in Europe—the overall survival rate now exceeds 90%, with many subtypes achieving cure rates approaching 95–100%.
1. What Is Wilms Tumour? Embryology and Pathogenesis
To understand Wilms tumour, one must understand kidney development. The kidneys develop from the intermediate mesoderm, specifically the metanephric blastema (metanephric mesenchyme) and the ureteric bud. The metanephric blastema differentiates into nephrons (the filtering units), while the ureteric bud forms the collecting system.
In normal development, the metanephric blastema undergoes mesenchymal-to-epithelial transition, induced by signals from the ureteric bud, and eventually exhausts itself, disappearing by 36 weeks of gestation.
Wilms tumour arises when primitive metanephric blastemal cells fail to differentiate and instead persist and proliferate malignantly. These “nephrogenic rests” are considered the precursor lesions. They are found in up to 1% of infant autopsies but only rarely progress to cancer.
Key Molecular Drivers
| Gene / Locus | Function | Role in Wilms Tumour |
|---|---|---|
| WT1 (11p13) | Transcription factor regulating renal development; tumour suppressor. | Mutated in ~10–15% of sporadic cases. Associated with WAGR syndrome, Denys-Drash syndrome. |
| WTX (AMER1, Xq11.1) | Regulates β-catenin degradation (Wnt pathway). | Inactivated in ~30% of tumours (somatic mutations). |
| CTNNB1 (β-catenin, 3p22) | Key effector of Wnt signaling. | Activating mutations in ~15% of tumours (often mutually exclusive with WTX). |
| TP53 (17p13) | “Guardian of the genome”; apoptosis/DNA repair. | Mutated almost exclusively in anaplastic histology; predicts poor prognosis. |
| 11p15 (IGF2/H19 locus) | Imprinted region controlling growth (Loss of Imprinting – LOI). | LOI leading to IGF2 overexpression is the most common molecular alteration (~70% of cases). |
| MiRNA Processing Genes (DROSHA, DGCR8, DICER1) | MicroRNA biogenesis. | Mutations found in a subset of blastemal-predominant tumours. |
Clinical Pearl: The shift from “one gene, one disease” to understanding Wilms tumour as a disorder of disrupted renal developmental pathways (Wnt/β-catenin, IGF2, p53) has allowed for risk stratification based on molecular biology, not just microscopy.
2. Epidemiology and Risk Factors
Incidence and Demographics
| Feature | Details |
|---|---|
| Incidence | About 650 new cases a year in the USA and 80–85 in the UK. |
| Age | Peak at 2–3 years; median 3.5 years (one kidney) and 2.5 years (both kidneys). |
| Sex | Slightly more common in girls. |
| Laterality | 95% one kidney; 5% both kidneys, more often in younger children and those with syndromes. |
| Ethnicity | Highest in Black children, lowest in East Asian children. |
Associated Congenital Anomalies and Syndromes
Approximately 10–15% of children with Wilms tumour have an underlying genetic syndrome or congenital anomaly. Recognition is critical for surveillance and genetic counselling.
| Syndrome / Association | Genetic Basis | Key Clinical Features | Wilms Tumour Risk |
|---|---|---|---|
| WAGR Syndrome | Contiguous gene deletion: 11p13 (WT1 + PAX6) | Wilms tumour, Aniridia, Genitourinary anomalies, Retardation (intellectual disability) | ~30–50% |
| Denys-Drash Syndrome | WT1 point mutations (dominant negative) | Early-onset nephrotic syndrome (diffuse mesangial sclerosis), pseudohermaphroditism (46,XY), high Wilms risk | >90% (often bilateral) |
| Beckwith-Wiedemann Syndrome (BWS) | 11p15 dysregulation (LOI, UPD, CDKN1C mut) | Macrosomia, macroglossia, omphalocele, hemihypertrophy, neonatal hypoglycemia, ear creases/pits | ~5–10% |
| Simpson-Golabi-Behmel Syndrome | GPC3 (Xq26) | Coarse facies, macrosomia, cardiac/renal anomalies, polydactyly | Increased |
| Perlman Syndrome | DIS3L2 | Macrosomia, facial dysmorphism, renal hamartomas, pancreatic hyperplasia | High |
| Isolated Hemihypertrophy | Often 11p15 LOI | Asymmetric limb/trunk growth | ~2.5–3% |
| Aniridia (Isolated) | PAX6 deletion/mutation | Absent iris | Risk if WT1 deleted (WAGR) |
Surveillance Protocol for High-Risk Groups: Children with BWS, hemihypertrophy, WAGR, or Denys-Drash should undergo abdominal ultrasound every 3 months until age 7–8 years (some protocols extend to age 16 for BWS due to later onset risk).
3. How Does It Look? (Pathology, Imaging, and Macroscopic Appearance)
This section details the visual characteristics of Wilms tumour across macroscopic pathology, microscopic histology, and radiological imaging.
3.1 Macroscopic (Gross) Pathology
When the surgeon or pathologist examines the removed kidney (nephrectomy specimen), classic Wilms tumour has a distinct appearance:
| Feature | Appearance |
|---|---|
| Edge | Well-defined, pushing the normal kidney aside. |
| Size | Often large (median 10–15 cm). |
| Cut surface | Soft, tan-grey tumour with bleeding, necrosis, cysts and sometimes calcification. |
| Vein extension | Tumour may grow into the renal vein and IVC. |
| Bilateral disease | Several nodules in both kidneys, often with nephrogenic rests. |
3.2 Microscopic Histology (The “Triphasic” Pattern)
The diagnosis is confirmed by light microscopy. The classic Wilms tumour is triphasic, recapitulating embryonic kidney development. The proportion of each component varies.
| Component | Microscopic Appearance | Significance |
|---|---|---|
| Blastemal | Most primitive/aggressive. Sheets of small, round, blue cells with scant cytoplasm, high nuclear-to-cytoplasmic ratio, frequent mitoses. Resembles metanephric blastema. | High blastemal volume correlates with chemotherapy resistance; Blastemal-predominant tumours after preoperative chemo = High Risk. |
| Stromal | Spindle cells (fibroblastic/myofibroblastic) in a loose myxoid to dense collagenous matrix. May show heterologous differentiation: skeletal muscle (rhabdomyoblastic), cartilage, bone, fat, glial tissue. | Generally favourable biology. Predominant stromal = Stromal-predominant type. |
| Epithelial | Differentiated. Tubules, glomeruloid structures, cysts lined by cuboidal/columnar epithelium. Resembles developing nephrons. | Indicates differentiation. Predominant epithelial = Epithelial-predominant type. |
Anaplasia: The Critical Adverse Feature
Anaplasia defines “Unfavourable Histology” (UH) and dictates intensified therapy. It is defined by three criteria (all three must be present):
1. Multipolar, abnormal mitotic figures (e.g., tripolar, quadrupolar spindles).
2. Marked nuclear enlargement (nuclei ≥ 3x size of adjacent non-anaplastic nuclei; hyperchromasia).
3. Hyperchromasia (coarse, clumped chromatin).
- Focal Anaplasia: Confined to one or a few discrete foci within the primary tumour and not present in lymph nodes or distant sites. Prognosis intermediate.
- Diffuse Anaplasia: Widespread throughout the tumour, or present in lymph nodes/peritoneal implants/spillage. Poor prognosis; requires aggressive multi-agent chemo + radiation.
Other Histological Subtypes (COG/SIOP Classification)
- Cystic Partially Differentiated Nephroblastoma (CPDN): Almost entirely cystic with low-grade epithelial lining. Benign behaviour; surgery alone curative.
- Mesoblastic Nephroma: Infantile renal tumour (usually < 3 months). Classic (fibroblastic) vs Cellular (infantile fibrosarcoma-like, ETV6-NTRK3 fusion). Not a Wilms tumour, but differential diagnosis.
- Clear Cell Sarcoma of the Kidney (CCSK): Distinct entity. “Chicken-wire” vascular pattern. Bone metastasis propensity. Not Wilms tumour.
- Rhabdoid Tumour of the Kidney (RTK): SMARCB1 (INI1) loss. Extremely aggressive. Occurs in infants. Not Wilms tumour.
3.3 Radiological Appearance (Imaging “Look”)
Ultrasound (US) – First Line Screening
| Ultrasound finding | Meaning |
|---|---|
| Large mixed solid mass | Typical Wilms tumour. |
| Claw (rim) sign | Kidney tissue wraps around the mass, confirming it arises from the kidney. |
| Doppler of vessels | Checks the renal vein and IVC for tumour thrombus. |
| Other kidney | Must be checked for a second tumour or nephrogenic rests. |
CT Scan (Chest/Abdomen/Pelvis) – Staging Standard (COG Protocol)
| CT finding | Meaning |
|---|---|
| Mixed enhancement | Necrosis and bleeding within the tumour. |
| Calcification | In 10–15%. |
| Local invasion | Spread into fat or nearby organs. |
| Nodes over 1 cm | Possible node spread. |
| Chest CT | Required; finds lung nodules missed on X-ray. |
MRI – Problem Solving / SIOP Preferred
- Superior Soft Tissue Contrast: Best for evaluating IVC/Right Atrium tumour thrombus extent (critical for surgical planning).
- No Ionizing Radiation: Preferred in SIOP protocols for response assessment during preoperative chemotherapy.
- Diffusion Weighted Imaging (DWI): Helps differentiate viable tumour (restricted diffusion) from necrosis/fibrosis post-chemo.
Imaging Differential Diagnosis Table
| Feature | Wilms Tumour | Neuroblastoma | Renal Cell Carcinoma (RCC) | Mesoblastic Nephroma |
|---|---|---|---|---|
| Typical Age | 2–5 years | < 3 years (infants) | Adolescents / Adults | < 3 months (Infants) |
| Origin | Intrarenal (Claw sign +) | Suprarenal/Adrenal (displaces kidney) | Intrarenal (cortical) | Intrarenal |
| Calcification | 10–15% (coarse) | 90%+ (fine, “stippled”) | Rare | Rare |
| Vascular Invasion | Renal Vein → IVC (common) | Encasement (rarely intravascular) | Renal Vein → IVC (common) | Rare |
| Metastases | Lungs > Liver > Nodes | Bone marrow, Bone, Liver, Nodes (Orbits) | Lungs, Bone, Liver, Brain | Rare (Cellular variant: lung) |
| Urine Catecholamines | Normal | Elevated (VMA/HVA) | Normal | Normal |
4. Symptoms: Clinical Presentation
Wilms tumour is often asymptomatic in early stages. The classic presentation is an asymptomatic abdominal mass discovered by a parent during bathing/dressing or by a paediatrician at a routine well-child check.
4.1 Local Symptoms (Mass Effect)
| Sign | How common | Notes |
|---|---|---|
| Abdominal mass | Most common sign. | Firm, smooth, painless; often found by parents. |
| Swollen tummy | Common. | Clothes feel tight. |
| Abdominal pain | 30–40%. | From stretching, bleeding or rupture; can mimic appendicitis. |
| High blood pressure | About 25%. | Caused by renin. |
| Blood in urine | 15–20%. | Tumour in the collecting system. |
| Left varicocele | Uncommon. | Blocked left renal vein; examine the scrotum. |
4.2 Constitutional / Systemic Symptoms
- Fatigue / Lethargy / Pallor: Due to anaemia (chronic disease, blood loss, marrow infiltration rare).
- Fever: Low-grade, unexplained (tumour necrosis, cytokine release – IL-6).
- Weight Loss / Anorexia / Failure to Thrive: Late signs, large tumour burden.
- Polycythemia (Rare): Erythropoietin production by tumour.
4.3 Metastatic Symptoms (Advanced Disease – Stage IV)
- Respiratory: Cough, dyspnoea, tachypnoea, chest pain (Lung metastases – most common site).
- Hepatomegaly / Right Upper Quadrant Mass: Liver metastases.
- Bone Pain / Limp / Pathological Fracture: Bone metastases (rare at diagnosis, more common in CCSK/Rhabdoid).
- Neurological: CNS metastases are exceedingly rare at diagnosis.
4.4 Paraneoplastic Syndromes (Rare)
- Cushing Syndrome: Ectopic ACTH production.
- Hypertrophic Osteoarthropathy: Clubbing, periostitis.
- Acquired von Willebrand Disease: Bleeding diathesis.
- Opsoclonus-Myoclonus Syndrome: (More typical of Neuroblastoma, but reported).
Red Flags Requiring Urgent Referral (2-Week Wait / Fast Track)
Any child with an abdominal mass must be referred immediately to a Paediatric Oncology Centre.
- Palpable abdominal mass (flank or midline).
- Unexplained macroscopic hematuria.
- Hypertension + abdominal mass.
- Abdominal distension + failure to thrive/weight loss.
5. Diagnostic Workup: Step-by-Step
5.1 Initial Laboratory Investigations
These assess baseline organ function and fitness for chemotherapy/surgery.
| Test | Purpose | Typical Findings / Action |
|---|---|---|
| CBC + Differential | Baseline haemoglobin, platelets, WBC (neutropenia risk). | Anaemia common; Thrombocytosis (reactive) or Thrombocytopenia (consumption). |
| Renal Function (U&E, Creatinine, eGFR) | Critical. Assess baseline GFR before nephrotoxic chemo (Cisplatin/Carboplatin). | Usually normal (compensatory hypertrophy of contralateral kidney). |
| Liver Function Tests (LFTs) | Baseline for chemo metabolism (Dactinomycin, Doxorubicin). | Usually normal; Liver mets → elevated ALP, GGT. |
| Coagulation (PT, aPTT, Fibrinogen) | Rule out DIC (rare) or acquired von Willebrand. | Usually normal. |
| Urinalysis + Culture | Rule out UTI; detect microscopic hematuria. | Hematuria ~20%; Proteinuria rare (unless renal vein thrombosis). |
| Urine Catecholamines (VMA/HVA) | Mandatory to exclude Neuroblastoma. | Normal in Wilms; Elevated in Neuroblastoma. |
| Chromosomal Analysis / Genetic Testing | Indicated if: Syndromic features, Bilateral disease, Aniridia, Hypospadias/Ambiguous genitalia, Family history. | Karyotype, WT1 sequencing, 11p15 methylation studies (BWS), Panel testing. |
5.2 Imaging Staging Workflow
- Abdominal Ultrasound: Confirm renal origin, check contralateral kidney, assess IVC/renal vein.
- Chest CT (High Resolution): Gold standard for pulmonary mets. (Chest X-ray insufficient).
- Abdominal CT or MRI: CT standard (COG); MRI preferred for venous thrombus extent & no radiation (SIOP).
- Bone Scan / PET-CT: Not routine. Only if bone pain, elevated ALP, or CCSK/Rhabdoid suspected.
5.3 Biopsy vs. Primary Nephrectomy (The Great Divide)
This is the fundamental difference between COG (North America) and SIOP (Europe/International) protocols.
| Feature | COG Approach (North America) | SIOP Approach (Europe/UK/International) |
|---|---|---|
| First Step | Primary Nephrectomy (Surgery First) | Preoperative Chemotherapy (4–6 weeks) |
| Rationale | Accurate primary staging & histology; avoids chemo in benign lesions (CPDN, Mesoblastic Nephroma); removes tumour burden immediately. | Shrinks tumour → easier surgery, less rupture/spillage (downstaging); treats micrometastases early; allows biology assessment (response). |
| Biopsy | Rarely done upfront (risk of upstaging to Stage III via spillage). | Mandatory core needle biopsy before chemo to confirm diagnosis & histology (except <6mo or typical imaging + normal catecholamines in some protocols). |
| Histology Grading | Primary Histology: Based on untreated tumour. | Post-Chemo Histology (SIOP Classification): Based on % necrosis/viable components after chemo. |
| Risk Stratification | Based on Stage + Primary Histology + Molecular (LOH 1p/16q). | Based on Stage + Post-Chemo Histology Risk Group (Low/Intermediate/High) + Molecular. |
Current Consensus: Both approaches yield equivalent excellent survival (>90%). Choice depends on institutional protocol. Centralised care in a Paediatric Oncology Principal Treatment Centre is non-negotiable.
6. Staging Systems
Staging determines prognosis and treatment intensity. Two systems coexist; they are not directly interchangeable.
6.1 COG Staging (Surgical/Pathological – Post-Nephrectomy)
Based on findings at surgery and final pathology of the primary tumour.
| Stage | Definition | Frequency | 4-Year OS (Favourable Histology) |
|---|---|---|---|
| I | Tumour limited to kidney, completely excised. Intact capsule. No vascular invasion. No residual tumour. | ~40% | >99% |
| II | Tumour extends beyond kidney (penetrates capsule, invades renal sinus/soft tissue/renal vein/IVC) but completely excised. No residual. | ~20% | >98% |
| III | Residual tumour post-surgery confined to abdomen. Positive margins, lymph nodes, peritoneal spillage/rupture (intraop or preop), biopsy prior to resection, implantation, residual tumour at margins. | ~25% | 90–95% |
| IV | Haematogenous metastases: Lung, Liver, Bone, Brain, Distant Nodes. | ~10% | 80–85% |
| V | Bilateral Renal Involvement at diagnosis. Each side staged separately (I–IV). | ~5% | 70–85% (Organ preservation key) |
6.2 SIOP Staging (Post-Chemotherapy / Post-Nephrectomy)
Based on extent of tumour after preoperative chemotherapy.
| Stage | Definition (Post-Chemo) |
|---|---|
| I | Tumour limited to kidney, pseudo-capsule intact, no penetration. May have necrotic tumor bed. |
| II | Tumour penetrates capsule / invades renal sinus / renal vein / IVC but completely resected. |
| III | Incomplete resection / Residual tumour in abdomen: Positive nodes, peritoneal implants, positive margins, tumour rupture/spillage (pre or intraop), preoperative biopsy. |
| IV | Distant metastases (Lung, Liver, Bone, Brain) present at diagnosis (persisting or resolved after chemo). |
| V | Bilateral disease. |
6.3 Histological Risk Groups (Treatment Drivers)
| Group | COG Definition | SIOP Definition (Post-Chemo) | Treatment Intensity |
|---|---|---|---|
| Low Risk | Stage I/II FH with specific molecular markers (no 1p/16q LOH) OR CPDN. | Low Risk: Completely necrotic (no viable cells) OR Cystic Partially Differentiated. | Surgery Only (or minimal chemo: Vincristine only). |
| Standard / Intermediate Risk | Stage I–III FH (most). Stage I–II Focal Anaplastic. | Intermediate Risk: Viable non-anaplastic cells (Regressive, Mixed, Blastemal, Stromal, Epithelial predominant). | Vincristine + Dactinomycin ( +/- Doxorubicin for Stage III/High volume). Radiotherapy for Stage III. |
| High Risk | Diffuse Anaplasia (Any Stage). Blastemal Predominant post-chemo (SIOP). Clear Cell Sarcoma / Rhabdoid. Molecular High Risk (TP53 mut, 1p/16q LOH + Stage III/IV). | High Risk: Diffuse Anaplasia, Blastemal Predominant (>65% viable blastema post-chemo). | Intensive Multi-agent Chemo (Vincristine, Dactinomycin, Doxorubicin, Cyclophosphamide, Etoposide, Carboplatin/Cisplatin) + Radiotherapy (Abdomen ± Whole Lung). |
| Very High / Experimental | Bilateral High Risk, Relapsed High Risk. | Similar. | Clinical Trials (e.g., ICE, Topotecan, Immunotherapy, HDCT/Autologous Stem Cell Rescue). |
7. Treatment Modalities: A Multimodal Approach
Treatment is risk-adapted. The goal is cure with minimal late effects.
7.1 Surgery (Nephrectomy)
- Radical Nephrectomy: Standard for unilateral disease. En-bloc removal of kidney, Gerota’s fascia, perirenal fat, ipsilateral adrenal gland (usually), and regional lymph nodes.
- Lymph Node Sampling (LND): Mandatory for accurate staging (COG: ≥ 7 nodes; SIOP: sampling). Positive nodes = Stage III.
- Minimally Invasive (Laparoscopic/Robotic): Acceptable for Stage I/II, tumours < 7–10cm, no venous thrombus, by experienced surgeons. Contraindicated if rupture risk high or thrombus present. Specimen retrieval bag mandatory.
- Bilateral Disease (Stage V): Nephron-Sparing Surgery (Partial Nephrectomy) is the standard. Goal: Preserve renal function, avoid dialysis/transplant. Performed after preoperative chemo shrinkage. Requires expert pediatric urologic oncology surgeon.
7.2 Chemotherapy Agents (Backbone)
| Drug | Class | Mechanism | Key Toxicities (Acute / Late) |
|---|---|---|---|
| Vincristine | Vinca Alkaloid | Microtubule inhibition (M-phase). | Neurotoxicity: Peripheral neuropathy (foot drop, constipation, jaw pain), SIADH. No myelosuppression. |
| Dactinomycin (Actinomycin D) | Antibiotic | DNA intercalation. | Myelosuppression (nadir 2–3 wks), Hepatotoxicity (VOD/SOS risk with radiation), Nausea/Vomiting, Radiation Sensitisation (Recall). |
| Doxorubicin | Anthracycline | Topoisomerase II inhibition, ROS generation. | Cardiotoxicity (Cumulative dose-dependent cardiomyopathy – Lifetime limit ~300-450 mg/m²), Myelosuppression, Alopecia, Mucositis, Secondary AML (dose-related). |
| Cyclophosphamide | Alkylating Agent | DNA cross-linking. | Haemorrhagic Cystitis (Mesna protection mandatory), Myelosuppression, Infertility (Gonadal toxicity – dose dependent), Alopecia, Secondary Malignancies (Bladder, AML). |
| Etoposide | Topoisomerase II Inhibitor | DNA strand breaks. | Myelosuppression, Secondary AML (t-AML) – often 11q23/MLL rearrangements, Mucositis, Hypotension (infusion rate). |
| Carboplatin / Cisplatin | Platinum Analogues | DNA cross-linking. | Nephrotoxicity (Cisplatin > Carbo), Ototoxicity (High freq hearing loss – irreversible), Neuropathy (Cisplatin), Myelosuppression (Carbo), Nausea (Cisplatin severe). |
7.3 Radiotherapy (RT)
- Indications: Stage III (Favourable Histology), All Diffuse Anaplasia, Stage IV (Whole Lung Irradiation – WLI – if incomplete response to chemo), Local relapse.
- Technique: Modern 3D-CRT / IMRT / VMAT / Proton Beam Therapy. Protons preferred for sparing liver, bowel, contralateral kidney, heart, spine (growth).
- Dose: Flank/Abdomen: 10.8–19.8 Gy (FH); 19.8–30 Gy (Anaplastic). WLI: 12–15 Gy.
- Late Effects: Scoliosis/Kyphosis (vertebral growth arrest), Renal dysfunction (contralateral kidney), Bowel obstruction (adhesions/fibrosis), Secondary malignancies (Sarcoma, Breast, GI tract in field), Endocrine (ovarian/testicular failure if pelvis irradiated).
7.4 Treatment by Risk Group (Simplified COG-style Algorithm)
Very Low Risk (Stage I FH, < 2 years, < 550g, No LOH 1p/16q)
- Surgery Only. No Chemo. No RT.
- Survival >99%.
Low Risk (Stage I/II FH, older/larger or LOH+)
- Regimen EE-4A: Vincristine (weekly x 12) + Dactinomycin (q 3-4 wks x 4–5 doses).
- Duration: ~19–25 weeks. No RT.
Standard Risk (Stage III FH, Stage I/II Focal Anaplastic)
- Regimen DD-4A: Vincristine + Dactinomycin + Doxorubicin (cumulative 150–300 mg/m²).
- Flank Radiation: 10.8–19.8 Gy (starts ~Week 1–2 of chemo).
- Duration: ~25–31 weeks.
High Risk (Diffuse Anaplasia, Stage IV FH, Blastemal Predominant post-chemo, CCSK, Rhabdoid)
- Regimen UH-1 / ICE / Regimen I: Intensive multi-agent.
- Cycles: Vincristine/Doxorubicin/Cyclophosphamide (VDC) alternating with Ifosfamide/Carboplatin/Etoposide (ICE) or Cyclophosphamide/Etoposide.
- Radiation: Higher doses, wider fields (Whole Abdomen if diffuse peritoneal spill; WLI for lung mets).
- High Dose Chemo + Autologous Stem Cell Rescue: Investigational/Standard for relapsed/refractory or very high risk primary (e.g., Bilateral Anaplastic).
8. Special Clinical Scenarios
8.1 Bilateral Wilms Tumour (Stage V) – The Nephron-Sparing Imperative
| Step | Details |
|---|---|
| Diagnosis | Usually treated without upfront biopsy when imaging is typical. |
| Chemotherapy first | 6–12 weeks of vincristine and dactinomycin, with or without doxorubicin, to shrink tumours. |
| Surgery | Nephron-sparing partial nephrectomies to keep as much kidney as possible. |
| Pathology | Response and anaplasia guide further treatment. |
| Outcome | About 85–90% 5-year survival; long-term kidney follow-up needed. |
8.2 Intravascular Tumour Thrombus (IVC/Right Atrium)
| Thrombus level | Surgical approach |
|---|---|
| I–II (below or at the liver) | Nephrectomy with removal of thrombus from the IVC. |
| III (behind the liver) | Liver mobilisation and vascular control. |
| IV (right atrium) | Cardiopulmonary bypass with a cardiac surgical team. |
Thrombus occurs in 4–10%. MRI or CT defines its level, and chemotherapy before surgery often shrinks it.
8.3 Tumour Rupture (Intraoperative or Preoperative)
- Definition: Spillage of viable tumour cells into peritoneal cavity.
- Staging: Automatic Stage III (COG & SIOP).
- Management: Meticulous peritoneal lavage (saline). Avoid tumour morcellation in laparoscopic bags if malignancy suspected.
- Treatment: Requires Abdominal Radiation (10.8–19.8 Gy) + 3-drug chemo (VDC). Survival remains excellent (~90%).
8.4 Relapsed / Refractory Disease
| Aspect | Details |
|---|---|
| Frequency | About 10–15% relapse; higher with anaplasia or stage IV. |
| Sites and timing | Lungs (about 50%), abdomen (about 30%), liver, bone; mostly within 2 years. |
| Poor signs | Anaplasia, advanced stage, early relapse, prior radiotherapy. |
| Treatment | Salvage chemotherapy (e.g. ICE, cyclophosphamide/etoposide), surgery and radiotherapy; high-dose chemotherapy with stem cell rescue in some. |
| Research | Targeted drugs and immunotherapy in clinical trials. |
9. Long-Term Follow-Up and Survivorship Care
With >90% cure rates, the focus has shifted to minimising late effects. Survivors require lifelong, risk-based follow-up (Children’s Oncology Group Long-Term Follow-Up Guidelines).
9.1 Renal Function (Critical)
- Single Kidney (Unilateral Nephrectomy): Hyperfiltration injury → Focal Segmental Glomerulosclerosis (FSGS) long-term.
- Monitoring: Annual BP, Urinalysis (proteinuria), Serum Creatinine/eGFR (Cystatin C preferred).
- Prevention: ACEi/ARB if proteinuria/hypertension. Avoid NSAIDs (Ibuprofen, Naproxen) chronically. Hydration. Medic alert bracelet: “Solitary Kidney”.
- Bilateral/NSS Survivors: Higher CKD risk (Stage 2–3 common). Nephrology co-management essential.
9.2 Cardiotoxicity (Anthracycline Exposure)
- Risk: Cumulative Doxorubicin dose > 300 mg/m² = significant risk.
- Screening: Echocardiogram (Echo) + ECG at entry into survivorship, then every 1–5 years based on dose/age at treatment/female sex/radiation to chest.
- Metrics: LVEF, Global Longitudinal Strain (GLS – earlier detector).
- Prevention: Dexrazoxane (cardioprotectant) used in some high-dose protocols. Lifelong heart-healthy lifestyle.
9.3 Gonadal Function / Fertility
- Females: Alkylators (Cyclophosphamide/Ifosfamide) + Abdominal/Pelvic RT → Ovarian Failure / Premature Menopause. AMH levels, FSH/LH monitoring. Oocyte/embryo cryopreservation if post-pubertal. Ovarian tissue cryopreservation (experimental/pre-pubertal).
- Males: Alkylators + RT → Leydig Cell (Testosterone) and Sertoli Cell (Spermatogenesis) failure. Sperm banking (post-pubertal). Testicular tissue cryopreservation (pre-pubertal, experimental).
- Pregnancy: High-risk obstetrics (renal/cardiac reserve). Uterine vascular insufficiency if flank RT.
9.4 Musculoskeletal / Growth
- Spinal Irradiation: Asymmetric growth → Scoliosis / Kyphosis / Reduced sitting height. Orthopaedic surveillance until skeletal maturity.
- Leg Length Discrepancy: Hemihypertrophy (syndrome) or radiation effect.
9.5 Second Malignant Neoplasms (SMN)
| Aspect | Details |
|---|---|
| Risk | About 1.5–3% by 20–30 years after treatment. |
| Leukaemia | Peaks 5–10 years after treatment; linked to etoposide, alkylators and radiation. |
| Solid tumours | Breast (after chest radiotherapy), sarcoma, thyroid, bowel, skin. |
| Surveillance | Yearly check-ups; breast MRI from age 25 or 8 years after chest radiotherapy; earlier colonoscopy after abdominal radiotherapy. |
9.6 Neurocognitive / Psychosocial
- Generally normal IQ if no CNS RT (rare).
- Risk: Young age at treatment, chronic illness stress, hearing loss (Cisplatin), vision issues.
- School: Neuropsychological testing if academic struggles. 504 Plan / IEP accommodations.
- Psychosocial: Anxiety, PTSD (parents/siblings too), transition to adult care. Survivorship Clinic model essential.
10. Prognosis and Survival Statistics
| Group | 5-Year Overall Survival (Approx.) | Event-Free Survival (Approx.) |
|---|---|---|
| Overall (All Stages/Histologies) | 90–93% | 80–85% |
| Favourable Histology (FH) – Stage I | >99% | >95% |
| FH – Stage II | 98–99% | 90–95% |
| FH – Stage III | 90–95% | 80–85% |
| FH – Stage IV (Lung only, good response) | 85–90% | 75–80% |
| FH – Stage IV (Liver/Bone/Poor response) | 70–80% | 60–70% |
| Focal Anaplasia (Stage I-II) | 90–95% | 80–85% |
| Diffuse Anaplasia (Any Stage) | 50–70% | 40–60% |
| Bilateral (Stage V) FH | 80–90% | 70–80% |
| Relapsed FH (Standard Risk) | 50–70% (with salvage + transplant) | – |
Note: “Cure” is generally defined as 5-year Event-Free Survival. Late relapses (>5 years) are rare but documented, particularly in anaplastic histology and after radiation.
11. Prevention and Screening Summary
| Population | Screening Modality | Frequency | Duration |
|---|---|---|---|
| General Population | None (No mass screening) | N/A | N/A |
| Beckwith-Wiedemann / Hemihypertrophy / Isolated Hemihypertrophy | Abdominal Ultrasound | Every 3 months | Until Age 7–8 years (Some extend to 16 for BWS) |
| WAGR / Denys-Drash / Perlman / Simpson-Golabi-Behmel | Abdominal Ultrasound | Every 3 months | Until Age 7–8 years (Denys-Drash: consider earlier/longer) |
| Previous Wilms Tumour Survivor | Chest CT (First 2-3 yrs), then CXR; Abdominal US/MRI; Renal Function; Echo | Per COG LTFU Guidelines (Risk-based) | Lifelong |
12. Key Takeaways for Families and Clinicians
- Wilms tumour is curable. >90% overall survival.
- Abdominal mass in a child = Urgent Ultrasound + Oncology Referral. Do not biopsy blindly in the community (rupture risk/upstaging).
- Hypertension is common. Check BP at every visit; treat aggressively to protect the remaining kidney.
- Treatment is Risk-Adapted. “Low risk” gets less therapy (surgery only or 2 drugs); “High risk” gets intensive multi-modal therapy.
- Bilateral disease = Nephron Sparing Surgery. Preserve kidney function at all costs.
- Long-term follow-up is NOT optional. Renal, Cardiac, Fertility, SMN surveillance saves lives decades later.
- Genetic Counselling. Offer to all families, especially if bilateral, syndromic features, or positive family history.
13. Resources and Further Reading (Harvard Style)
Clinical Guidelines & Protocols
- Children’s Oncology Group (COG). (2023) AREN0532 / AREN0533 / AREN1921 Protocol Documents. Available at: https://childrensoncologygroup.org/ (Accessed: October 2026).
- International Society of Paediatric Oncology (SIOP) Renal Tumour Study Group (RTSG). (2022) SIOP WT 2001 / UMBRELLA / SIOP-RTGS 2016 Protocols. Available at: https://www.siop-rtsg.org/ (Accessed: October 2026).
- National Comprehensive Cancer Network (NCCN). (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Wilms Tumor (Nephroblastoma). Version 2.2023. Available at: https://www.nccn.org/ (Accessed: October 2026).
- Children’s Oncology Group. (2023) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 6.0. Available at: https://www.survivorshipguidelines.org/ (Accessed: October 2026).
Key Textbooks & Reviews
- Dome, J.S., Fernandez, C.V., Mullen, E.A. et al. (2021) ‘Children’s Oncology Group’s 2013 blueprint for research: Renal tumors’, Pediatric Blood & Cancer, 68(Suppl 2), p.e28361.
- Graf, N., van den Heuvel-Eibrink, M.M., van Tinteren, H. et al. (2019) ‘The SIOP renal tumour studies: 50 years of international collaboration’, Nature Reviews Clinical Oncology, 16(11), pp. 685–696.
- Pritchard-Jones, K., Bergeron, C., de Camargo, B. et al. (2020) ‘Wilms tumour’, The Lancet, 395(10230), pp. 1039–1051.
- Pizer, B.L. and Davenport, R. (eds.) (2022) Pediatric Oncology: A Comprehensive Guide. 3rd edn. Cham: Springer Nature. Chapter: Renal Tumours.
- Huff, V. (2019) ‘Wilms tumor genetics’, American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 181(3), pp. 312–321.
Genetics & Molecular Pathology
- Koepsell, S.A., Murphy, K.M., Dehner, L.P. et al. (2020) ‘Recurrent DROSHA and DICER1 mutations in blastemal-predominant Wilms tumors’, Modern Pathology, 33(1), pp. 168–178.
- Scott, R.H., Stiller, C.A., Walker, L. et al. (2018) ‘Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice’, Archives of Disease in Childhood, 103(12), pp. 1154–1160.
- Williams, R.D., Al-Saadi, R., Chagtai, T. et al. (2021) ‘Subtype-specific molecular profiles of Wilms tumor define new therapeutic targets’, Nature Communications, 12, p. 1234.
Patient & Family Support Organizations
- Children’s Cancer and Leukaemia Group (CCLG) (UK): Wilms Tumour – A Parent’s Guide. Available at: https://www.cclg.org.uk/
- American Cancer Society: Wilms Tumor (Nephroblastoma) Detailed Guide. Available at: https://www.cancer.org/
- Kids Cancer Support Group / Wilms Tumor Foundation: Patient advocacy and research funding.
- Macmillan Cancer Support: Wilms tumour information.
Landmark Historical Papers (Context)
- Wilms, M. (1899) ‘Die Mischgeschwülste der Niere’, Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medicin, 156(1), pp. 1–67. (Original description).
- D’Angio, G.J., Evans, A.E., Breslow, N. et al. (1989) ‘Treatment of Wilms’ tumor. Results of the Third National Wilms’ Tumor Study’, Cancer, 64(2), pp. 357–364. (Established modern multimodal therapy).
Appendix: Glossary of Common Terms
| Term | Definition |
|---|---|
| Anaplasia | Microscopic feature (large distorted nuclei, abnormal mitoses) indicating aggressive behaviour/unfavourable histology. |
| Blastema / Blastemal | Primitive, undifferentiated embryonic kidney cells; the “blue cell” component of Wilms. |
| CPDN | Cystic Partially Differentiated Nephroblastoma – a benign cystic variant cured by surgery alone. |
| eGFR | Estimated Glomerular Filtration Rate – measure of kidney function. |
| FH / UH | Favourable Histology / Unfavourable Histology (synonymous with Anaplastic). |
| Gerota’s Fascia | Fibrous capsule surrounding the kidney and perirenal fat. |
| HDCT / AuSCT | High-Dose Chemotherapy with Autologous Stem Cell Transplant (Rescue). |
| IGF2 | Insulin-like Growth Factor 2 – fetal growth promoter overexpressed in 70% Wilms via 11p15 LOI. |
| IVC | Inferior Vena Cava – large vein returning blood to heart; tumour thrombus extends here. |
| LND | Lymph Node Dissection / Sampling – critical for Stage III assignment. |
| LOH | Loss of Heterozygosity – loss of one allele (e.g., 1p, 16q, 11p, 17p) indicating tumour suppressor loss. |
| LOI | Loss of Imprinting – epigenetic silencing of maternal H19 leading to biallelic IGF2 expression. |
| Metachronous | Occurring at different times (e.g., tumour in opposite kidney appearing years later). |
| NSS | Nephron-Sparing Surgery (Partial Nephrectomy). |
| RT | Radiotherapy / Radiation Therapy. |
| SIOP / COG | International Society of Paediatric Oncology / Children’s Oncology Group. |
| SMN | Second Malignant Neoplasm (therapy-induced). |
| VOD / SOS | Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (liver toxicity from Dactinomycin + RT). |
| WT1 / WTX | Wilms Tumour 1 gene / Wilms Tumour X-linked gene – key tumour suppressors. |